Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
2011

Using PET Scans to Improve Treatment for Hodgkin's Lymphoma

Sample size: 360 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yvette L. Kasamon

Primary Institution: Johns Hopkins University School of Medicine

Hypothesis

Can prognostic information from midtreatment PET scans guide more individualized therapy for Hodgkin's lymphoma?

Conclusion

Midtreatment PET scans can provide valuable prognostic information that may help tailor treatment strategies for Hodgkin's lymphoma patients.

Supporting Evidence

  • FDG-PET performed after 2 cycles of ABVD chemotherapy provides valuable prognostic information.
  • Negative interim PET scans are associated with a high 2-year progression-free survival rate.
  • Positive interim PET scans indicate a higher risk of treatment failure.

Takeaway

Doctors can use special scans to see how well treatment is working for patients with Hodgkin's lymphoma, which helps them decide the best way to continue treatment.

Methodology

The study reviews the use of FDG-PET scans for assessing treatment response in Hodgkin's lymphoma and discusses various clinical trials and their outcomes.

Potential Biases

Potential biases may arise from the retrospective nature of some studies and the variability in PET scanning techniques.

Limitations

The variability in PET scan interpretation and the need for standardized criteria may affect the generalizability of the findings.

Participant Demographics

The majority of participants were adults with advanced Hodgkin's lymphoma.

Statistical Information

P-Value

0.007

Confidence Interval

95% confidence interval, 0.72 to 0.89

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2011/271595

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication